[PDF] Top 20 Estilos de crianza en niños y niñas de 0 a 3 años de edad
Has 10000 "Estilos de crianza en niños y niñas de 0 a 3 años de edad" found on our website. Below are the top 20 most common "Estilos de crianza en niños y niñas de 0 a 3 años de edad".
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
... invasive cancer in the breast at the time of surgery, was significantly higher in patients treated with lapatinib and trastuzumab than with trastuzumab alone ...supporting dual blockage of the HER ... See full document
24
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
... of HER2-positive breast cancers do not show substantial clinical benefit from the targeted therapy and, thus, the mechanisms underlying resistance remain partially ...2,096 breast tumours, we ... See full document
36
Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial
... advanced, HER2-positive breast ...a positive predictor for PEH treatment ...care, dual HER2-blockade strategies have significantly improve pCR rate [8, ...the ... See full document
167
The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
... biological treatment for their ...hormonal treatment for MBC before randomiza- ...received neoadjuvant or adjuvant chemotherapy with or without trastuzumab, provided, in this case, that ... See full document
14
HER2 amplification level is not a prognostic factor for HER2- positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis
... of HER2 amplification were associated with a significantly longer PFS or a significantly higher objective response rate (ORR) ...of HER2 amplification as a good predictive biomarker both for early ... See full document
11
Current neoadjuvant treatment options for HER2 positive breast cancer
... with breast cancer demonstrate amplification of the human epidermal receptor type 2 (HER2) gene, the expression of which is associated with a relatively poor prognosis independent of other clinical ... See full document
65
HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
... 115 HER2-positive BC patients receiving trastuzumab treatment were enrolled in the ...status, cancer stage, expression of hormone receptor, amplification of HER2, and treatment ... See full document
10
Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients
... Eight (6.6%) patients missed at least one cycle of doc- etaxel; three of them refused to complete the planned treat- ment, two of whom achieved complete clinical responses before completing planned docetaxel. Two ... See full document
16
Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
... the neoadjuvant setting has been emerging as a promising research tool in BC, providing an excellent plat- form for clinical development of novel anticancer agents, and an extraordinary source of tumor tissues for ... See full document
6
Potential of afatinib in the treatment of patients with HER2-positive breast cancer
... on HER2 inhibitors. Breast cancer can persistently depend on HER2-dependent signaling pathways HER2- dependent signaling pathways and, consequently a continuous HER2 inhibition ... See full document
51
Role of pertuzumab in the treatment of HER2-positive breast cancer
... treatment directed against individual members of this family is a successful strategy for cancer ...that HER2/neu overexpression is not required for it to be an active ...metastatic HER2 ... See full document
20
New developments in the treatment of HER2-positive breast cancer
... metastatic breast cancers show increased expression of the human epidermal growth factor receptor-2 (HER2) tyrosine ...Two HER2-specific therapies are currently approved for clinical treatment ... See full document
21
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
... across treatment arms. Patients treated with dual anti-HER2 blockade plus docetaxel showed higher rates of pCR, as compared to other treatment arms, in low and intermediate TILs groups, ... See full document
30
<p>Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis</p>
... in breast cancer is a preoperative treatment, which is initially applied locally to advanced tumors to downgrade primary tumor and regional lymph nodes and enable their removal by ...Currently, ... See full document
99
Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
... the treatment of breast ...on breast cancer cells that express this tyrosine kinase ...as HER2-positive breast ...metastatic breast cancer; however, ... See full document
116
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients
... in HER2- negative patients, suggesting that miR-21 may be a specific biomarker of resistance for HER2-positive breast cancer (Table ...30 HER2-positive breast ... See full document
50
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
... the treatment groups was found for diarrhea ...anti-HER2 treatment started after anthracycline) than in the nonan- thracycline cohort (Table S6 in the Supplementary ...the treatment groups for ... See full document
5
The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review
... (enHANced treatment with NeoAdjuvant Herceptin)), was a parallel-group, open-label RCT (n = 595) directly comparing IV with SC administration of trastuzumab during 1 year of treat- ment and 2 years of ... See full document
5
Negative genic switch of HER 2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2 positive breast cancer
... by breast tissue micro- array (TMA) and matched node TMA that biomarkers’ status of metastatic nodal lesions could be a more accur- ate measurement for guiding adjuvant ... See full document
76
Increased Mortality Risk among Early Stage Hormone Receptor Positive Breast Cancer Patients Who Did Not Receive Adjuvant or Neoadjuvant Therapy
... receiving neoadjuvant/adjuvant therapy as well as a 45% reduction in mortality risk compared to patients who did not have the ...on adjuvant treatment decisions, reported that the additional ... See full document
72
Related subjects